Lenumlostat
PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively) ; PAT-1251 is used in the research of fibrotic diseases[1].
Product Specifications
CAS Number
2007885-39-2
Product Name Alternative
PAT-1251; GB2064
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Monoamine Oxidase
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lenumlostat.html
Purity
99.52
Solubility
DMSO : ≥ 130 mg/mL|H2O : ≥ 100 mg/mL
Smiles
O=C(C1=CC=CC(OC2=NC(C(F)(F)F)=CC(CN)=C2)=C1)N3C[C@@H](F)[C@H](O)C3
Molecular Formula
C18H17F4N3O3
Molecular Weight
399.34
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
In Vitro Model. 2025 Mar 7;4 (1) :59-69.|Cell Chem Biol. 2024 Jul 9:S2451-9456 (24) 00273-3.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GCDFP-15 (Gross Cystic Disease Fluid Protein 15) (Breast Marker) (PIP/1571), CF740 conjugate, 0.1mg/mL
